» Articles » PMID: 38356971

INSULIN RESISTANCE AND PATHOGENESIS OF POSTMENOPAUSAL OSTEOPOROSIS

Overview
Specialty Endocrinology
Date 2024 Feb 15
PMID 38356971
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoporosis (OP) is a disease predisposing postmenopausal women to fractures, and often accompanied by insulin resistance (IR) and metabolic syndrome (MetS). Previous studies provided contradictory results concerning prevalence of MetS in postmenopausal OP. To better understand the pathogenesis of IR, we reviewed cellular and molecular aspects and systematically reviewed studies providing homeostasis model assessment (HOMA) index. Bone is an active endocrine organ maintaining its integrity by orchestrated balance between bone formation and resorption. Both osteoblasts and osteoclasts contain receptors for insulin and insulin-like growth factor-1 (IGF-1) operating in skeletal development and in the adult life. Defects in this system generate systemic IR and bone-specific IR, which in turn regulates glucose homeostasis and energy metabolism through osteocalcin. Examination of genetic syndromes of extreme IR revealed intriguing features namely high bone mineral density (BMD) or accelerated growth. Studies of moderate forms of IR in postmenopausal women reveal positive correlations between HOMA index and BMD while correlations with osteocalcin were rather negative. The relation with obesity remains complex involving regulatory factors such as leptin and adiponectin to which the contribution of potential genetic factors and in particular, the correlation with the degree of obesity or body composition should be added.

Citing Articles

Fine-Scale Haplotype Mapping Reveals an Association of the Gene with Osteoporosis and Fracture Risk in Postmenopausal Women.

Greere D, Haydar S, Grigorescu F, Manda D, Voicu G, Lautier C Genes (Basel). 2024; 15(9).

PMID: 39336743 PMC: 11431166. DOI: 10.3390/genes15091152.


Relative Contribution of Metabolic Syndrome Components in Relation to Obesity and Insulin Resistance in Postmenopausal Osteoporosis.

Greere D, Grigorescu F, Manda D, Voicu G, Lautier C, Nitu I J Clin Med. 2024; 13(9).

PMID: 38731059 PMC: 11084230. DOI: 10.3390/jcm13092529.

References
1.
Tonk C, Shoushrah S, Babczyk P, El Khaldi-Hansen B, Schulze M, Herten M . Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?. Int J Mol Sci. 2022; 23(3). PMC: 8836178. DOI: 10.3390/ijms23031393. View

2.
Liu P, Ilich J, Brummel-Smith K, Ghosh S . New insight into fat, muscle and bone relationship in women: determining the threshold at which body fat assumes negative relationship with bone mineral density. Int J Prev Med. 2014; 5(11):1452-63. PMC: 4274553. View

3.
Li Q, Zhao Y, Wang Y, Yang Y, He S, Zhang X . Correlation Between Serum 25(OH)D and Abdominal Visceral Fat Area in Patients with Type 2 Diabetes Mellitus in the Context of different Bone Mass. Acta Endocrinol (Buchar). 2022; 17(3):351-357. PMC: 8919490. DOI: 10.4183/aeb.2021.351. View

4.
Florencio-Silva R, Sasso G, Sasso-Cerri E, Simoes M, Cerri P . Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. Biomed Res Int. 2015; 2015:421746. PMC: 4515490. DOI: 10.1155/2015/421746. View

5.
Nasu M, Sugimoto T, Chihara M, Hiraumi M, Kurimoto F, Chihara K . Effect of natural menopause on serum levels of IGF-I and IGF-binding proteins: relationship with bone mineral density and lipid metabolism in perimenopausal women. Eur J Endocrinol. 1997; 136(6):608-16. DOI: 10.1530/eje.0.1360608. View